Media Coverage
Back to Media CoverageSIGILON FINDS PARTNER IN LILLY FOR T1D ENCAPSULATED CELL THERAPY
Sigilon Therapeutics Inc. (Cambridge, Mass.) granted Eli Lilly and Co. (NYSE:LLY) exclusive, worldwide rights to Sigilon’sType I diabetes program in a deal potentially worth over $470 million.